ispinesib

DRUG14 trials

Sponsors

GlaxoSmithKline, National Cancer Institute (NCI), NCIC Clinical Trials Group, Cytokinetics

Conditions

Acute Undifferentiated LeukemiaAdenocarcinoma of the ProstateAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)

Phase 1

SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes

CompletedNCT00098826

National Cancer Institute (NCI)Acute Undifferentiated Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) +24

Start: 2004-12-31Updated: 2013-01-11

SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma

TerminatedNCT00101244

National Cancer Institute (NCI)Adult Grade III Lymphomatoid Granulomatosis, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma +30

Start: 2004-11-30Updated: 2013-01-14

Ispinesib In Combination With Capecitabine In Patients With Solid Tumors

CompletedNCT00119171

GlaxoSmithKlineSolid Tumor Cancer

Start: 2004-11-30Target: 30Updated: 2008-10-16

Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma

CompletedNCT00363272

National Cancer Institute (NCI)Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor +22

Start: 2006-06-30Updated: 2013-01-16

A Study of Ispinesib in Metastatic Breast Cancer

TerminatedNCT00607841

CytokineticsBreast Neoplasms

Start: 2007-12-31End: 2009-11-30Updated: 2019-05-06

Phase 2

Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer

CompletedNCT00085813

GlaxoSmithKlineNon-Small-Cell Lung Cancer

Start: 2003-12-31End: 2005-10-31Target: 70Updated: 2010-10-04

Study Of Ispinesib In Subjects With Breast Cancer

CompletedNCT00089973

GlaxoSmithKlineNeoplasms, Breast

Start: 2004-06-30End: 2006-08-25Updated: 2018-02-26

SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

CompletedNCT00095628

National Cancer Institute (NCI)Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer +19

Start: 2005-01-31End: 2010-07-31Updated: 2017-03-06

SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer

CompletedNCT00095992

NCIC Clinical Trials GroupLiver Cancer

Start: 2005-03-08End: 2008-09-22Updated: 2023-08-04

SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma

CompletedNCT00095953

NCIC Clinical Trials GroupMelanoma (Skin)

Start: 2004-11-30End: 2008-09-30Updated: 2013-05-17

SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel

CompletedNCT00096499

National Cancer Institute (NCI)Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer

Start: 2005-04-30Updated: 2013-01-25

Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ovarian Cancer

CompletedNCT00097409

GlaxoSmithKlineOvarian Cancer

Start: 2004-12-31End: 2007-05-31Updated: 2010-10-04

SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer

CompletedNCT00103311

National Cancer Institute (NCI)Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IIIA Colon Cancer +9

Start: 2005-01-31End: 2010-09-30Updated: 2015-03-02

Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer

CompletedNCT00354250

National Cancer Institute (NCI)Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer

Start: 2006-05-31Updated: 2013-06-05